Free Trial

Tandem Diabetes Care Q3 2024 Earnings Report

Tandem Diabetes Care logo
$19.15 -0.13 (-0.67%)
As of 12:02 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Tandem Diabetes Care EPS Results

Actual EPS
-$0.35
Consensus EPS
-$0.43
Beat/Miss
Beat by +$0.08
One Year Ago EPS
-$0.38

Tandem Diabetes Care Revenue Results

Actual Revenue
$243.97 million
Expected Revenue
$224.14 million
Beat/Miss
Beat by +$19.83 million
YoY Revenue Growth
+31.40%

Tandem Diabetes Care Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Remove Ads

Tandem Diabetes Care Earnings Headlines

3 Reasons to Sell TNDM and 1 Stock to Buy Instead
Trump’s Final Plan
Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’s secret plan to trigger the greatest transfer of wealth since FDR and LBJ – trillions of dollars could be redistributed.
Lake Street Keeps Their Buy Rating on Tandem Diabetes Care (TNDM)
See More Tandem Diabetes Care Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tandem Diabetes Care? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tandem Diabetes Care and other key companies, straight to your email.

About Tandem Diabetes Care

Tandem Diabetes Care (NASDAQ:TNDM), a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

View Tandem Diabetes Care Profile

More Earnings Resources from MarketBeat